Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts broadly favor Vera Therapeutics: Fourteen firms give the stock a consensus “Moderate Buy” rating, including 11 buys and one strong buy. The average 12-month price target is $80.15, well above the reported $35.05 share price.
• Vera reported quarterly EPS of -$1.52, beating the consensus estimate of -$1.58, though analysts expect a full-year loss of approximately $6.44 per share.
• Institutional investors own 99.21% of the company, while insiders have sold 83,250 shares worth about $3.31 million over the past three months. Vera is developing atacicept, an investigational treatment for immune-mediated diseases.

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $80.1538.

Several equities analysts have recently commented on VERA shares. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research report on Wednesday, July 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Friday, July 17th. Guggenheim increased their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. William Blair reiterated an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, The Goldman Sachs Group reiterated a "buy" rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd.

Vera Therapeutics Stock Up 4.3%

Shares of NASDAQ:VERA opened at $35.05 on Friday. The firm has a market cap of $2.53 billion, a PE ratio of -5.98 and a beta of 0.96. The company has a fifty day simple moving average of $35.11 and a 200 day simple moving average of $37.18. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics has a 12-month low of $22.72 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating analysts' consensus estimates of ($1.58) by $0.06. During the same quarter in the prior year, the company earned ($1.20) EPS. On average, equities research analysts anticipate that Vera Therapeutics will post -6.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,250 shares of company stock valued at $3,307,800 over the last three months. Insiders own 15.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter valued at about $46,000. Quantbot Technologies LP bought a new position in Vera Therapeutics in the second quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $71,000. Nykredit A S acquired a new position in Vera Therapeutics in the second quarter valued at approximately $97,000. Finally, Tower Research Capital LLC TRC boosted its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after acquiring an additional 2,757 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company's research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera's leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.